Fragile X Syndrome (FXS)

Spinogenix’s SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome

FDA grants fast-track designation to small molecule for Fragile X

FDA grants orphan designation to Fragile X syndrome therapeutic

Spinogenix’s SPG601 Earns Orphan Drug Designation for Fragile X Syndrome

FDA clears Phase 2 trial of oral SPG601 in men with fragile X

FDA clears investigational new drug application for Fragile X treatment

Two major breakthroughs in Fragile X Syndrome treatments

Spinogenix’s Investigational New Drug Application for Novel Treatment for Fragile X Syndrome Cleared to Begin Phase II Trial